Project Term
–
Project Summary
Over the past year, we explored whether there is a biological basis that helps explain why African and African American patients typically present with more aggressive forms of lymphoma, which tend to be less responsive to treatments. Our findings revealed that, in addition to having slightly different mutations in the lymphoma cells, the tissue microenvironment surrounding these cells is rich in cells that suppress the immune response. We were the first to describe this type of cell, which is also commonly observed in other patients with less responsive tumors. We discovered that these mutations might make lymphoma cells more likely to respond to novel targeted therapies that are not yet available in clinical settings. Furthermore, we developed innovative therapeutic strategies aimed at targeting the microenvironment cells to enhance the immune response against these tumors. These studies were conducted using pre-clinical models as a precursor to clinical trials. We anticipate that these studies will benefit patients with high-risk diffuse large B cell lymphoma, regardless of their ethnicity. To help identify patients more likely to respond to these treatments, we are developing minimally invasive biomarkers that use a drop of blood to analyze specific characteristics in both lymphoma and microenvironment cells. This approach is crucial for reducing reliance on biopsies and tissue analysis, which can be challenging or cumbersome to obtain from patients. Over the past year, we have continued to investigate how epigenetic drugs can be used in combination with immune therapies to increase the likelihood of curing lymphoma patients. We have several ongoing clinical trials exploring the concept that administering epigenetic drugs can make tumors more susceptible to being destroyed by immune cells, either naturally present in the body or administered via blood transfusion. In these patients, we also apply biomarkers to determine which individuals can benefit most from epigenetic therapy and to understand how and when the drugs modify the microenvironment, allowing us to decide the optimal timing for immune cell transfusion.
Lay Abstract
Our research delves deeper into the complex interplay between lymphoma cells and their microenvironment, revealing how this dynamic relationship not only supports tumor growth but also actively suppresses the immune system’s capacity to mount an effective response. We discovered several ways different cell types help lymphoma cells grow while also impacting the immune system. These mechanisms allow lymphoma cells to avoid being recognized by immune cells, like T cells, or to produce substances that make immune cells inactive. By understanding these processes, we could think about ways to use drugs to block them, helping immune cells regain their ability to fight cancer cells. Since we found several unique mechanisms, and not all are present in every patient, we needed to create tools to identify which mechanism is active in each case. This means that the biomarker will guide the clinician in choosing the best drug for the patient. We have several clinical trials underway, some nearing completion, to test these ideas. Building on these findings, our research aims to deepen the understanding of how the interaction between lymphoma cells and their surroundings affects disease progression and treatment resistance. By identifying the specific immune-suppressive cells within the tumor environment, we are uncovering new ways lymphoma cells avoid immune detection and destruction. This knowledge is helping us design targeted therapies that not only attack the cancer cells directly but also change the surrounding environment to boost the body’s natural immune response. These dual-action strategies show promise for overcoming the limitations of current treatments, especially for patients with aggressive lymphoma types that have historically responded poorly to standard therapies. Altogether, these efforts are paving the way for more effective, personalized treatments that could improve outcomes for patients with high-risk Our research delves deeper into the complex interplay between lymphoma cells and their microenvironment, revealing how this dynamic relationship not only supports tumor growth but also actively suppresses the immune system’s capacity to mount an effective response. By dissecting the cellular and molecular mechanisms involved, we have identified specific immune-suppressive cells and signaling pathways that lymphoma cells exploit to evade immune surveillance. These findings underscore the heterogeneity of the tumor microenvironment across patients, emphasizing the need for personalized diagnostic tools that can accurately detect the dominant immune evasion mechanisms in each case. Such precision in biomarker identification is critical for tailoring therapeutic strategies, enabling clinicians to select drugs that specifically disrupt these immune-suppressive interactions, thereby restoring immune cell function and enhancing anti-tumor immunity. Building on these insights, our ongoing clinical trials are testing novel combination therapies designed to simultaneously target lymphoma cells and modulate their surrounding environment. These dual-action approaches aim to overcome the limitations of existing treatments, particularly for aggressive lymphoma subtypes that have shown resistance to conventional therapies. By reprogramming the tumor microenvironment to favor immune activation, these therapies hold promise for improving patient outcomes and achieving durable responses. Ultimately, this research paves the way for more effective, individualized treatment regimens that integrate tumor biology and immune contexture, offering new hope for patients with high-risk diffuse large B cell lymphoma across diverse demographic groups.
Program
